Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

不一致的分析和查,查看克拉米迪亚形虫.

J Schachter, W E Stamm, T C Quinn

    Lancet (London, England)
    |February 5, 1998
    PubMed
    概括

    No abstract available in PubMed .

    相关实验视频

    相关概念视频

    您也可能阅读

    相关文章

    通过共同作者、期刊和引用图与本文相关的文章。

    排序
    Same author

    Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·2025
    Same author

    Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.

    Annals of oncology : official journal of the European Society for Medical Oncology·2024
    Same author

    Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285].

    Annals of oncology : official journal of the European Society for Medical Oncology·2022
    Same author

    Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021
    Same author

    Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2021